Diflucan® Partnership Program

Partnership objectives

  1. Improve the quality of life for people living with HIV and AIDS.
  2. Enhance capacity of healthcare professionals through on-line training modules in order to support the diagnosis, treatment and management of HIV- related opportunistic infections.

Private–public partnerships are instrumental in achieving the program’s objectives of ensuring an uninterrupted access to the much needed anti-fungal medicine. Private–public partnerships are instrumental in achieving the program’s objectives of ensuring an uninterrupted access to the much needed anti-fungal medicine. Copyright Pfizer

What are the health needs and challenges?

Increased access to HIV and AIDS treatment has improved prognosis of HIV-infected patient. However many patients continue to die of HIV-related opportunistic infections. In Sub-Saharan alone, more than 500,000 deaths are attributed to crypotococcal meningitis.

Prevention and treatment of HIV-related opportunistic infection is an important part of care for people with HIV and AIDS, since these conditions continue to cause high morbidity in infected patients throughout the world. 

Description of partnership activities and how they address needs and challenges

As part of the commitment to increasing the availability of medicines for those most in need, Pfizer created the Diflucan® Partnership Program (DPP) on the 1st of December 2000. Through this program, Diflucan® (fluconazole), an antifungal medicine is provided free of charge to governmental and nongovernmental organizations in developing countries with greater than 1% HIV and AIDS prevalence, for the treatment of two fungal opportunistic infections associated with HIV and AIDS.

The administrative partner, Direct Relief, has been commisssioned to provide technical assistance, supports program management and manage the distribution of Diflucan to participating governments and organizations. Pfizer also develops and distributes materials to support patient education and health care professional training.

Lessons learned

  • Private–public partnerships are instrumental in achieving the program’s objectives of ensuring an uninterrupted access to a much needed anti-fungal medicine. Close collaboration between Pfizer and Direct Relief is helping align Diflucan® demand & supply processes i.e. ensuring adequate Inventory levels, increased stock turnover and reduced POS obsolescence at the warehouse. 
  • Inventory Management and Control— Limited capacity to account for existing stock at site level & poor reporting from health facilities can lead to over/under-supply of sites and possible unreported expiry of product.

Summary of impact and forward looking information

Globally the program has donated more than $1.6 billion USD in medicine to more than 6,081 sites in 63 countries in Africa, Asia, the Caribbean and Latin America.

  • Improved operational efficiencies and developed Interactive Map to ensure access to comprehensive distribution data for the program.

There continues to be a significant shift in the HIV and AIDS environment since 2000 when the epidemic was widespread; and HIV medicines were unavailable and unaffordable. Today new studies indicate that the Cryptococcal antigen is detectable in the blood several weeks to months before symptomatic disease occurs, and that early treatment with Fluconazole can prevent progression to meningitis and the associated high mortality rates. Pfizer is, therefore, looking at the developments more broadly to explore feasible options and collaborative efforts to ensure a sustainable solution.


10 Anniversary of the Diflucan

Partnership information

Company(ies) Pfizer

Partner(s) Axios International, Direct Relief, Interchurch Medical Assistance (IMA), International Association of Physicians in AIDS Care, International Dispensary Association (IDA)

Type of Partner(s) NGOs, Other Business, Professional Associations

Therapeutic Focus Vaccine-Preventable Diseases, Infectious Diseases

Disease(s) HIV/AIDS, Meningitis C

Program Type(s) Availability of Treatment - Product Donations, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) Children, Marginalised / Indigenous People, Men, Mothers, People with low income, Women, Youth

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Sub-Saharan Africa

Number of Countries 62

Country(ies) Antigua and Barbuda, Barbados, Belize, Benin, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Chad, Congo, Cook Islands, Costa Rica, Côte d'Ivoire, Democratic Republic of the Congo, Dominica, Dominican Republic, El Salvador, Ethiopia, Fiji, Ghana, Grenada, Guatemala, Guinea-Bissau, Guyana, Haiti, Honduras, Kenya, Kiribati, Lesotho, Malawi, Mali, Marshall Islands, Micronesia, Mozambique, Namibia, Nigeria, Niue, Palau, Panama, Papua New Guinea, Rwanda, Samoa, Senegal, Solomon Islands, South Africa, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Swaziland, Tanzania, The Gambia, Togo, Tonga, Trinidad and Tobago, Tuvalu, Uganda, Uzbekistan, Vanuatu, Vietnam, Zambia, Zimbabwe

Start Date 2000

More information Diflucan Partnership Program

Anticipated completion date Ongoing

« The Diflucan Donation program remains critical to our patients. Without the drug being available through this program, our patients with cryptococcal meningitis would not be able to be treated. »

Mr. Dennis Palmer, Cameroon Baptist Convention Health Board (CBCHB)